Personalised dupilumab therapy in severe asthma: real-world dosing interval prolongation among early responders. (PubMed, J Allergy Clin Immunol Pract) - Oct 25, 2026 - "The majority of dupilumab early responders were able to successfully prolong their dosing interval while maintaining disease control. This in turn may have implications for drug costs and patient convenience."
Journal • Real-world evidence • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases
|
|
Arlene Shaw; Brian Lipworth; Philipp Suter; Robert Greig; Rory Chan
|